---
title: "Baiyunshan Q1 Revenue Rises as Profit Margins Narrow and Cash Outflows Ease"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/284209913.md"
description: "Guangzhou Baiyunshan Pharmaceutical Holdings reported a 3.58% year-on-year increase in Q1 2026 revenue, totaling RMB23.28 billion. However, net profit attributable to shareholders fell by 2.06% to RMB1.78 billion, with total profit down 1.04%. Despite this, underlying profitability improved, with net profit after non-recurring items rising 1.72% and operating cash outflows narrowing by 43.10%. The company's earnings per share decreased to RMB1.097, indicating a challenging profit environment, while total assets and shareholders’ equity grew by 6.21% and 4.69%, respectively. The market cap stands at HK$39.99B, with a YTD price performance of -5.19%."
datetime: "2026-04-27T11:10:36.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/284209913.md)
  - [en](https://longbridge.com/en/news/284209913.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/284209913.md)
---

# Baiyunshan Q1 Revenue Rises as Profit Margins Narrow and Cash Outflows Ease

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Guangzhou Baiyunshan Pharmaceutical Holdings Company ( (HK:0874) ) has issued an announcement.

Guangzhou Baiyunshan Pharmaceutical Holdings reported first-quarter 2026 operating revenue of RMB23.28 billion, up 3.58% year on year, while net profit attributable to shareholders slipped 2.06% to RMB1.78 billion as total profit edged down 1.04%. Underlying profitability was slightly stronger, with net profit after deducting non-recurring items rising 1.72%, operating cash outflows narrowing by 43.10%, and total assets and shareholders’ equity increasing 6.21% and 4.69% respectively, signaling continued balance-sheet expansion despite mild pressure on headline earnings.

The company’s basic and diluted earnings per share both fell to RMB1.097, and its weighted average return on net assets declined by 0.34 percentage point to 4.61%, indicating modest compression in returns even as the scale of the business grew. The combination of higher revenue, improved quality of recurring earnings, and reduced operating cash strain suggests that Baiyunshan is maintaining operational resilience but faces a more challenging profit environment that stakeholders will watch closely for margin and efficiency trends.

**More about Guangzhou Baiyunshan Pharmaceutical Holdings Company**

Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited is a Chinese joint stock company listed in Hong Kong that operates in the pharmaceutical industry. The group focuses on manufacturing and distributing medicines and related healthcare products, serving both domestic and international markets through its diversified portfolio of drug and health product businesses.

**YTD Price Performance:** -5.19%

**Average Trading Volume:** 1,374,623

**Technical Sentiment Signal:** Sell

**Current Market Cap:** HK$39.99B

For an in-depth examination of 0874 stock, go to TipRanks’ Overview page.

### Related Stocks

- [600332.CN](https://longbridge.com/en/quote/600332.CN.md)
- [00874.HK](https://longbridge.com/en/quote/00874.HK.md)

## Related News & Research

- [What Madrigal Pharmaceuticals (MDGL)'s Wider Q1 Losses and Rezdiffra Revenue Momentum Mean For Shareholders](https://longbridge.com/en/news/286674743.md)
- [Sensorion Appoints Fred Chereau as Chief Executive Officer](https://longbridge.com/en/news/286719182.md)
- [When Can We Expect A Profit From Island Pharmaceuticals Limited (ASX:ILA)?](https://longbridge.com/en/news/286861950.md)
- [How Strong UGN-103 Phase 3 Durability Data At UroGen Pharma (URGN) Has Changed Its Investment Story](https://longbridge.com/en/news/286658162.md)
- [Corbus Pharmaceuticals (CRBP) Receives a Buy from LifeSci Capital](https://longbridge.com/en/news/286648720.md)